...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!
Message: Re: PAH
It is described as an "extension" of the previous pilot trial (conducted by Laval Universite) https://clinicaltrials.gov/ct2/show/NCT03655704 Which was completed.
I found a P2 with investigator U of Laval P2 (Approach2). "Not yet recruiting" is the status and may have been abandoned (?): https://clinicaltrials.gov/ct2/show/NCT04915300
The extension referred to in this new trial appears to be sponsored by the NIH*.
https://phassociation.org/apabetalone-for-pulmonary-arterial-hypertension-a-pilot-study-approach-p/
Population: PAH
Start Date: June 14, 2022
End Date: October 14, 2022
Phase: Observational
*Institution: NIH
The main objective of this proposal is to extend the investigator’s preclinical findings on the role of epigenetics and DNA damage and Bromodomain-Containing Protein 4 (BRD4) inhibition as a therapy for a devastating disease, pulmonary arterial hypertension (PAH).
9 Recommendations
Loading...
Loading...
New Message
Please
login
to post a reply